Crovalimab Side Effects

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Applies to crovalimab: parenteral injection for iv use, parenteral injection for sub-q use.

Side effects include:

Adverse effects (≥10%): Infusion-related reactions, respiratory tract infections, viral infections, type III hypersensitivity reactions.

For healthcare professionals

Applies to crovalimab: injectable solution.

General adverse events

The most common adverse reactions occurring in at least 10% of patients who were either treatment naive or previously treated with a complement C5 inhibitor included infusion-related reaction, respiratory tract infection, and viral infection.^[Ref]

Dermatologic

• Common (1% to 10%): Rash/skin exfoliation

Gastrointestinal

• Common (1% to 10%): Diarrhea (including infectious), nausea

Hypersensitivity

• Very common (10% or more): Type III hypersensitivity reaction In patients switching from this drug to another C5 inhibitor (up to 25%), type III hypersensitivity reaction In patients switching from another C5 inhibitor to this drug (up to 19.4%), infusion-related reaction including anaphylaxis (up to 16%)
• Common (1% to 10%): Injection-related or injection-site reaction

Adverse reactions/symptoms associated with Type III hypersensitivity reactions included arthralgia, rash, pyrexia, myalgia, headache, fatigue, petechiae, abdominal pain, and renal abnormalities.

Infusion-related reactions or systemic injection-related reactions may include hypersensitivity reactions (including anaphylaxis) but also a range of other symptoms such as injection-site pain, erythema, headache, or myalgia.

Metabolic

• Common (1% to 10%): Hyperuricemia

Musculoskeletal

• Common (1% to 10%): Arthralgia

Nervous system

• Very common (10% or more): Headache/migraine (up to 11%)

Other

• Very common (10% or more): Viral infections including COVID-19, influenza, RSV, and herpes (up to 23%), peripheral edema/swelling (up to 11%)
• Common (1% to 10%): Fatigue/malaise/asthenia

Respiratory

• Very common (10% or more): Respiratory tract infection (up to 18%)

Respiratory tract infections included nasopharyngitis, pharyngitis, rhinitis, rhinitis allergic, upper respiratory tract infection, and pneumonia.

See also:

Further information

Crovalimab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer